Tina B McKay1, James Rhee2, Katia Colon3, Katherine Adelsberger3, Isabella Turco3, Ariel Mueller3, Jason Qu3, Oluwaseun Akeju3. 1. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: tmckay@mgh.harvard.edu. 2. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA; Corrigan Minehan Heart Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.
Abstract
OBJECTIVES: The objective of this study was to identify novel serum biomarkers specific to postoperative delirium after major cardiac surgery to provide insight into the pathologic processes involved in delirium and its sequelae. DESIGN: Nested, case-control study. SETTING: Cardiac surgical intensive care unit in a single-site hospital setting. PARTICIPANTS: The study comprised 24 older adults (aged >60 years) undergoing major cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was a positive screen for delirium from postoperative days one through three based on criteria included in the long form of the Confusion Assessment Method. A multiplexed proteomic approach was applied using proximity extension assays to identify and quantify proteins found in serum collected on the day of surgery and postoperative day one in delirious and nondelirious patient cohorts. An increase in serum fibroblast growth factor (FGF)-21 levels was identified in the delirious cohort from a presurgery baseline of (mean ± standard deviation) 5.0 ± 1.1 log2 abundance (95% confidence interval [CI], 4.3-5.7) to 6.7 ± 1.6 log2 abundance (95% CI, 5.7-7.7; p = 0.01) postsurgery. A similar increase was identified in FGF-23 from a presurgery baseline of 1.7 ± 1.3 log2 abundance (95% CI, 0.8-2.5) to 3.4 ± 2.2 log2 abundance (95% CI, 2.0-4.8; p = 0.06) postsurgery. An increase in interleukin-6 serum levels also was identified in the delirious cohort from a presurgery baseline of 3.8 ± 1.1 log2 abundance (95% CI, 3.1-4.5) to 8.7 ± 1.9 log2 abundance (95% CI, 7.5-9.9; p < 0.0001) postsurgery. However, the increase in interleukin-6 serum levels of the nondelirious cohort also met the study's threshold for statistical significance (p < 0.0001). Finally, an increase in monocyte chemotactic protein-3 serum levels was identified in the delirious cohort from a presurgery baseline of 4.1 ± 0.9 log2 abundance (95% CI, 3.6-4.7) to 6.1 ± 2.0 log2 abundance (95% CI, 4.8-7; p = 0.009) postsurgery. CONCLUSIONS: FGF-21, FGF-23, interleukin-6, and monocyte chemotactic protein-3 serum levels were increased postoperatively in patients who developed delirium after major cardiac surgery. This study identified two members of the FGF family as potential putative systemic biomarkers for postoperative delirium after cardiac surgery, suggesting a possible role for metabolic recovery in the pathophysiologic mechanisms underlying neurocognitive dysfunction.
OBJECTIVES: The objective of this study was to identify novel serum biomarkers specific to postoperative delirium after major cardiac surgery to provide insight into the pathologic processes involved in delirium and its sequelae. DESIGN: Nested, case-control study. SETTING: Cardiac surgical intensive care unit in a single-site hospital setting. PARTICIPANTS: The study comprised 24 older adults (aged >60 years) undergoing major cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was a positive screen for delirium from postoperative days one through three based on criteria included in the long form of the Confusion Assessment Method. A multiplexed proteomic approach was applied using proximity extension assays to identify and quantify proteins found in serum collected on the day of surgery and postoperative day one in delirious and nondelirious patient cohorts. An increase in serum fibroblast growth factor (FGF)-21 levels was identified in the delirious cohort from a presurgery baseline of (mean ± standard deviation) 5.0 ± 1.1 log2 abundance (95% confidence interval [CI], 4.3-5.7) to 6.7 ± 1.6 log2 abundance (95% CI, 5.7-7.7; p = 0.01) postsurgery. A similar increase was identified in FGF-23 from a presurgery baseline of 1.7 ± 1.3 log2 abundance (95% CI, 0.8-2.5) to 3.4 ± 2.2 log2 abundance (95% CI, 2.0-4.8; p = 0.06) postsurgery. An increase in interleukin-6 serum levels also was identified in the delirious cohort from a presurgery baseline of 3.8 ± 1.1 log2 abundance (95% CI, 3.1-4.5) to 8.7 ± 1.9 log2 abundance (95% CI, 7.5-9.9; p < 0.0001) postsurgery. However, the increase in interleukin-6 serum levels of the nondelirious cohort also met the study's threshold for statistical significance (p < 0.0001). Finally, an increase in monocyte chemotactic protein-3 serum levels was identified in the delirious cohort from a presurgery baseline of 4.1 ± 0.9 log2 abundance (95% CI, 3.6-4.7) to 6.1 ± 2.0 log2 abundance (95% CI, 4.8-7; p = 0.009) postsurgery. CONCLUSIONS: FGF-21, FGF-23, interleukin-6, and monocyte chemotactic protein-3 serum levels were increased postoperatively in patients who developed delirium after major cardiac surgery. This study identified two members of the FGF family as potential putative systemic biomarkers for postoperative delirium after cardiac surgery, suggesting a possible role for metabolic recovery in the pathophysiologic mechanisms underlying neurocognitive dysfunction.
Authors: Sarinnapha M Vasunilashorn; Long H Ngo; Noel Y Chan; Wenxiao Zhou; Simon T Dillon; Hasan H Otu; Sharon K Inouye; Iris Wyrobnik; George A Kuchel; Janet E McElhaney; Zhongcong Xie; David C Alsop; Richard N Jones; Towia A Libermann; Edward R Marcantonio Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-16 Impact factor: 6.053
Authors: David Brealey; Michael Brand; Iain Hargreaves; Simon Heales; John Land; Ryszard Smolenski; Nathan A Davies; Chris E Cooper; Mervyn Singer Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: Martin Lundberg; Anna Eriksson; Bonnie Tran; Erika Assarsson; Simon Fredriksson Journal: Nucleic Acids Res Date: 2011-06-06 Impact factor: 16.971
Authors: Cheng Chen; Bernard M Y Cheung; Annette W K Tso; Yudong Wang; Lawrence S C Law; Kwok Leung Ong; Nelson M S Wat; Aimin Xu; Karen S L Lam Journal: Diabetes Care Date: 2011-07-12 Impact factor: 19.112
Authors: Emer R McGrath; Jayandra J Himali; Daniel Levy; Sarah C Conner; Matthew P Pase; Carmela R Abraham; Paul Courchesne; Claudia L Satizabal; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri Journal: PLoS One Date: 2019-03-04 Impact factor: 3.240
Authors: Cristal M Hill; Thomas Laeger; Madeleine Dehner; Diana C Albarado; Blaise Clarke; Desiree Wanders; Susan J Burke; J Jason Collier; Emily Qualls-Creekmore; Samantha M Solon-Biet; Stephen J Simpson; Hans-Rudolf Berthoud; Heike Münzberg; Christopher D Morrison Journal: Cell Rep Date: 2019-06-04 Impact factor: 9.423
Authors: Daniel A Nation; Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Lina M D'Orazio; Maricarmen Pachicano; Farshid Sepehrband; Amy R Nelson; David P Buennagel; Michael G Harrington; Tammie L S Benzinger; Anne M Fagan; John M Ringman; Lon S Schneider; John C Morris; Helena C Chui; Meng Law; Arthur W Toga; Berislav V Zlokovic Journal: Nat Med Date: 2019-01-14 Impact factor: 53.440
Authors: Monika Sadlonova; Jonathan Vogelgsang; Claudia Lange; Irina Günther; Adriana Wiesent; Charlotte Eberhard; Julia Ehrentraut; Mareike Kirsch; Niels Hansen; Hermann Esselmann; Charles Timäus; Thomas Asendorf; Benedict Breitling; Mohammed Chebbok; Stephanie Heinemann; Christopher Celano; Ingo Kutschka; Jens Wiltfang; Hassina Baraki; Christine A F von Arnim Journal: BMC Cardiovasc Disord Date: 2022-06-30 Impact factor: 2.174